

FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LASALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7707

TELEPHONE (858) 552-1311

COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

July 29, 2003

MORGAN L. FITCH, JR.
FRANCIS A. EVEN*
JULIUS TABIN
JOHN F. FLANNERY
ROBERT B. JONES
JAMES J. SCHUMANN
JAMES J. HAMILL
TIMOTHY E. LEVSTIK
JOSEPH E. SHIPLEY
KENNETH H. SAMPLES
PHILIP T. PETTI
JOSEPH T. NABOR
STEVEN C. SCHROER
RICHARD A. KABA*
KARL R. FINK
MARK W. HETZLER
TIMOTHY P. MALONEY
JAMES P. KRUEGER
STEPHEN S. FAVAKEH
EDWARD W. GRAY, JR.*
RICHARD E. WAWRZYNIAK
STEVEN G. PARMELEE
SHERRI N. BLOUNT*
BRUCE R. MANSFIELD
KENDREW H. COLTON*
G. PAUL EDGELL*
RICHARD W. SCHUMACHER
MICHAEL A. SANZO*

CHRISTOPHER E. GEORGE*
SCOTT J. MENGHINI
EDWARD E. CLAIR
SANDRA V. SCAVO
JON A. BIRMINGHAM
RUDY KRATZ
RAMON R. HOCH*
JOHN E. LYHUS
STEVEN M. FREELAND
DONNA E. BECKER
SEAN R. O'DOWD
MICHAEL G. VRANICAR
BRIAN S. CLISE
MARTIN R. BADER
DEREK L. PRESTIN
MARK A. BORSOS
DAVID R. JAGLOWSKI
W. BRIAN EDGE*

PATENT AGENTS

ERIC J. WHITESSELL
JONATHAN H. BACKENSTOSE
LILIA I. SAFONOV

OF COUNSEL

THOMAS F. LEBENS
GEORGE W. SPELLMIRE, JR.
LISA M. SOMMER

03807 U.S. PRO
10/628309
07/29/03

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MS Patent Application
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Re: Continuation Patent Application
(Continuation of U.S. application no. 10/121,683)
Appl. No.: to be assigned
Filed: herewith
For: Novel Compounds with Analgesic Effect
Inventor(s): Pelcman, *et al.*
Atty. Dkt.: 7567/80568

Sir:

The following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. A copy of application no. 10/121,683, as filed in the U.S. Patent and Trademark Office on April 15, 2002, comprising:

a title page naming Benjamin Pelcman and Edward Roberts
as inventors (unnumbered)
51 pages of specification (numbered as pages 1-51),
12 pages of claims (numbered as pages 52-63), and
a one page abstract (numbered as page 64); and

*ADMITTED TO D.C. BAR; D.C. PRACTICE OF
ALL OTHERS LIMITED TO FEDERAL COURTS
AND AGENCIES

2. A copy of the originally executed Declaration (37 C.F.R. § 1.63) and Power of Attorney filed in predecessor application 09/029,468 (4 pages);
3. Preliminary Amendment (3 pages);
4. A copy of the originally executed and recorded Assignment to Astra Pharma Inc. filed in the parent application (4 pages);
5. A copy of the recorded Merger document assigning rights from Astra Pharma Inc. to AstraZeneca Canada Inc. (6 pages); and
6. Information Disclosure Statement (2 pages);
7. Form PTO-1449, List of References Cited by Applicant (2 pages);
8. Two (2) return postcards.

This application is a continuation of U.S. application no. 10/121,683, filed on April 15, 2002, which is a division of U.S. application no. 09/645,565, filed on August 25, 2000 (now U.S. 6,399,635). The '565 application is a division of U.S. application 09/029,468, filed on March 3, 1998 (now U.S. patent 6,153,626). The '468 application represented U.S. national phase of PCT/SE97/02051, with an international filing date of December 9, 1997, and claims priority to Swedish application no. 9604786-5, filed on December 20, 1996.

The entire disclosure of the prior applications, from which an oath or declaration is being supplied herewith in copy form, is considered a part of the disclosure of the accompanying continuation application and is hereby incorporated by reference.

In accordance with the requirements of 37 C.F.R. § 1.53(b), the present continuation application is being filed under the conditions specified in 35 U.S.C. § 120. The inventors named on this continuation application are the same as the inventors named on the parent, and the application is being filed before the patenting, or abandonment of, or termination of proceedings of the parent application (10/121,683).

We are submitting an Information Disclosure Statement which cites references originally submitted in connection with the parent application (09/121,683), and the predecessor applications. The present application relies upon 09/121,683 for priority under 35 U.S.C. § 120. Thus, in accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not being submitted. If, for



Commissioner of Patents
July 29, 2003
Page 3

any reason, the Examiner cannot locate a listed reference, Applicants will be happy to submit a copy as a courtesy.

Fee Calculation

Applicants calculate the filing fee is as follows:

	Total		No. Extra	Rate	Fee
Basic Filing Fee					750.00
Total Claims Fee	35	20=	15	\$ 18.00	270.00
Independent Claims Fee	13	3 =	10	\$ 84.00	840.00
Multiple Dependent Claims Fee				\$ 280.00	280.00
TOTAL FEES DUE					\$ 2,140.00

The application is being filed under 37 C.F.R. § 1.53 without the filing fee.

It is respectfully requested that the enclosed postpaid postcards be stamped with the serial number and the date the enclosed documents are received by the PTO and that they be returned as soon as possible.

Respectfully requested,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

MAS:ct
Enclosures